Market Cap 147.35M
Revenue (ttm) 0.00
Net Income (ttm) -81.31M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 573,600
Avg Vol 605,228
Day's Range N/A - N/A
Shares Out 25.19M
Stochastic %K 40%
Beta 0.63
Analysts Strong Sell
Price Target $80.60

Company Profile

Cybin Inc., a clinical-stage neuropsychiatry company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. It develops CYB003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder (MDD); and CYB004, a deuterated N, N-dimethyltryptamine (DMT), which is in phase 2 clinical trial for treating generalized anxiety disorders. The company also develops SPL028 injectable deuterated DMT completed phase 1 clinical...

Industry: Biotechnology
Sector: Healthcare
Website: cybin.com
Address:
100 King Street West, Suite 5600, Toronto, Canada
stoxx0007
stoxx0007 Oct. 14 at 11:50 PM
$GHRS $MNMD $CYBN $CMPS $PSIL Very Bold prediction right here.... And I agree 💯% ... 1,000% !!!🔥
0 · Reply
SonGoku
SonGoku Oct. 14 at 7:53 PM
$ATAI Interesting, I was told to look at this one. So far pretty impressed with a quick glance. $MNMD $CYBN
0 · Reply
BobJohnBuoy666
BobJohnBuoy666 Oct. 14 at 6:53 PM
$CMPS up over 50% since it gained top of descending wedge as support; waiting for $CYBN to catch up
0 · Reply
PsychedStocks
PsychedStocks Oct. 14 at 6:52 PM
$CYBN sweet recovery
0 · Reply
thepalace2007
thepalace2007 Oct. 14 at 6:25 PM
$CYBN buyout rumor again let’s go to $30
1 · Reply
Mastacash
Mastacash Oct. 14 at 4:26 PM
0 · Reply
BobJohnBuoy666
BobJohnBuoy666 Oct. 14 at 4:22 PM
$CYBN shares available to borrow jumped from 7k to 250k, borrow rate at 2.9%, short interest 16.42%. Early sign of possible covering.
0 · Reply
BobJohnBuoy666
BobJohnBuoy666 Oct. 14 at 4:02 PM
$CYBN completely wrong. The convertible debenture financing announced June 30th is a strategic move to give them flexibility while looking towards commercialization, and IMO, being viewed as a potential acquisition target for another company. They do not want to be in a cash poor position where they could be low balled; having the convertible debenture in place is strategic business planning, NOT an example of “death spiral financing”
0 · Reply
cambruck7
cambruck7 Oct. 14 at 2:42 PM
$CYBN Really sucks lelu was right lol. If you go back to their posts in June and July when the death spiral financing was announced they literally called everything perfectly. Cybin was tracking along with all the other psychedelics until the financing. Now all the others are up making new highs, while High Trail has just been nuking the price dumping shares since then. Just gotta hope most of the $50 million has been chewed through with the elevated volume past couple of months and we start to bounce. And please god hope they don't take another $50 million tranche. Been really hard to see and super frustrating, Cybin starting to not even be mentioned along with the other psychedelic stocks any more, despite going after a larger market, with a differentiated approach, and being in phase 3 trials for MDD, and having a second asset in phase 2 for GAD. Up is down, down is up, this management team is awful.
2 · Reply
PsychedStocks
PsychedStocks Oct. 14 at 2:14 PM
$CYBN recovering since Canadian markets were closed yesterday
1 · Reply
Latest News on CYBN
Cybin Announces Senior Leadership Changes

Sep 2, 2025, 7:30 AM EDT - 6 weeks ago

Cybin Announces Senior Leadership Changes


Cybin Announces Results of Annual Meeting of Shareholders

Aug 18, 2025, 5:30 PM EDT - 2 months ago

Cybin Announces Results of Annual Meeting of Shareholders


Cybin to Participate in the 2025 Psychedelic Science Conference

Jun 11, 2025, 7:30 AM EDT - 4 months ago

Cybin to Participate in the 2025 Psychedelic Science Conference


Cybin: Top Value Psychedelic Stock

Oct 15, 2024, 12:30 PM EDT - 1 year ago

Cybin: Top Value Psychedelic Stock


'We're Pretty Cheap At The Moment' - Cybin CEO Doug Drysdale

Sep 19, 2024, 8:00 AM EDT - 1 year ago

'We're Pretty Cheap At The Moment' - Cybin CEO Doug Drysdale


stoxx0007
stoxx0007 Oct. 14 at 11:50 PM
$GHRS $MNMD $CYBN $CMPS $PSIL Very Bold prediction right here.... And I agree 💯% ... 1,000% !!!🔥
0 · Reply
SonGoku
SonGoku Oct. 14 at 7:53 PM
$ATAI Interesting, I was told to look at this one. So far pretty impressed with a quick glance. $MNMD $CYBN
0 · Reply
BobJohnBuoy666
BobJohnBuoy666 Oct. 14 at 6:53 PM
$CMPS up over 50% since it gained top of descending wedge as support; waiting for $CYBN to catch up
0 · Reply
PsychedStocks
PsychedStocks Oct. 14 at 6:52 PM
$CYBN sweet recovery
0 · Reply
thepalace2007
thepalace2007 Oct. 14 at 6:25 PM
$CYBN buyout rumor again let’s go to $30
1 · Reply
Mastacash
Mastacash Oct. 14 at 4:26 PM
0 · Reply
BobJohnBuoy666
BobJohnBuoy666 Oct. 14 at 4:22 PM
$CYBN shares available to borrow jumped from 7k to 250k, borrow rate at 2.9%, short interest 16.42%. Early sign of possible covering.
0 · Reply
BobJohnBuoy666
BobJohnBuoy666 Oct. 14 at 4:02 PM
$CYBN completely wrong. The convertible debenture financing announced June 30th is a strategic move to give them flexibility while looking towards commercialization, and IMO, being viewed as a potential acquisition target for another company. They do not want to be in a cash poor position where they could be low balled; having the convertible debenture in place is strategic business planning, NOT an example of “death spiral financing”
0 · Reply
cambruck7
cambruck7 Oct. 14 at 2:42 PM
$CYBN Really sucks lelu was right lol. If you go back to their posts in June and July when the death spiral financing was announced they literally called everything perfectly. Cybin was tracking along with all the other psychedelics until the financing. Now all the others are up making new highs, while High Trail has just been nuking the price dumping shares since then. Just gotta hope most of the $50 million has been chewed through with the elevated volume past couple of months and we start to bounce. And please god hope they don't take another $50 million tranche. Been really hard to see and super frustrating, Cybin starting to not even be mentioned along with the other psychedelic stocks any more, despite going after a larger market, with a differentiated approach, and being in phase 3 trials for MDD, and having a second asset in phase 2 for GAD. Up is down, down is up, this management team is awful.
2 · Reply
PsychedStocks
PsychedStocks Oct. 14 at 2:14 PM
$CYBN recovering since Canadian markets were closed yesterday
1 · Reply
Ottway
Ottway Oct. 14 at 1:52 PM
$CYBN $ATAI $MNMD should be higher than both …
1 · Reply
Nicki001
Nicki001 Oct. 14 at 1:16 PM
$CYBN | Investment View: BUY Cybin is advancing as one of the few late-stage psychedelic biotech firms, with its lead compound CYB003 (a deuterated psilocin analog) now in Phase 3 for Major Depressive Disorder. The company recently secured MHRA approval for the U.K. arm of its pivotal program, partnered with Thermo Fisher Scientific for U.S.-based manufacturing, and entered a commercial prep collaboration with Osmind, reaching over 800 psychiatry clinics. Cybin maintains a solid cash position of ~$119M, strengthened by a new $50M private placement, and continues to expand IP protection around its core assets. The transition to Interim CEO Eric So provides strategic continuity as the firm moves toward commercialization. At ~$6.00, the stock appears undervalued relative to its clinical progress and regulatory positioning. Rating: BUY | 12-month target: $15–20 | Catalyst: Phase 3 readout (CYB003
0 · Reply
LiquidThetaLEAPS
LiquidThetaLEAPS Oct. 14 at 4:56 AM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $CYBN Current Share Price: $6.02 Contracts: $CYBN May 15, 2026 $8 Calls Scale in: $1.53- $1.87 Scale out: $2.38-$3.06 Can Easily Capture: 60% ROI Blended DTE: 214 Days | Join Elites here: https://liquidtheta.com/options
0 · Reply
Profitsalways
Profitsalways Oct. 13 at 8:12 PM
$CYBN as you know it will not exist 12 months from now, mark this
0 · Reply
HughJasol
HughJasol Oct. 13 at 7:03 PM
$CYBN the only stock I own that is red today… of course, it’s Cybin.
0 · Reply
Schaf
Schaf Oct. 13 at 6:46 PM
$CYBN this thing going to zero?
1 · Reply
grumpygoose
grumpygoose Oct. 13 at 6:07 PM
$CYBN oh looks it's red again
0 · Reply
ZRadly
ZRadly Oct. 13 at 2:44 PM
$CYBN whos still here?🤣 Lol look at UAMY 🤪🤑🤑🤑 told you!
0 · Reply
BobJohnBuoy666
BobJohnBuoy666 Oct. 13 at 2:25 PM
$CMPS and $MNMD look like they want to chug higher, poor $CYBN looking like Sleepy Joe
0 · Reply
BOXLinvestor
BOXLinvestor Oct. 12 at 12:35 PM
$CYBN Cybin (option volume 10-10-25) 6.02 −4.0% | 122 trades | total $95.5K | 90-day avg $47.7K × 2.00 call $94.5K | put $1.1K | 61% single-leg, 39% multi-leg
0 · Reply
brunoq14
brunoq14 Oct. 11 at 10:30 AM
$CYBN Who else has demonstrated long term remission?
0 · Reply
microdoseme
microdoseme Oct. 10 at 8:27 PM
$CYBN I still believe CYBIN will be in the hunt once the dust settles.
0 · Reply